AK117 (Anti-CD47 mAb) Plus Cetuximab or AK104 (Anti-PD-1/CTLA-4 bsAb) as Second-Line Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Clinical trial NCT06508606 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06508606
- Sponsor
- West China Hospital
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-08-01
- Primary completion
- 2026-11-01
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.